CITCO (20 mg/kg) has been safely provided to hCAR-transgenic mice over six days as an adjuvant to enhance the tumour suppressing effects of the chemotherapy combination “CHOP”, which contains cyclophosphamide, doxorubicin, vincristine, and prednisone [153]. This evidence concerns the gene CXADR and neoplasm.